In short, he'll be further along the learning curve than anyone ever tapped for the nation's number-one public health regulatory slot.
Trump reiterates call to bring down drug prices; Novartis renews its focus on immunotherapies; a new bill would allow drugs to be imported
Despite budgets bouncing back from a decrease in 2015, big threats have appeared that may temper future plans, Iskowitz writes.
In short, the Trump team, I predict, will seek to tweak FDA.
Finally, a Congress and president who see pharma as a resource and not a villain, Flaum writes.
Pharma execs raise concerns about Trump's plans for the FDA; Merck ends study of experimental Alzheimer's drug; Amgen seeks new indication for Blincyto
Last week President Trump told drugmakers that 'the pricing has been astronomical.'
It's hard to be against the concept of reform, but Trump is better known for epithets than policy details, Kamp writes.
A Haymarket Media survey of more than 700 client-side marcomms execs in the US reveals the shift in power will not significantly affect budgets.
A new survey found that 34% of healthcare and pharma marketers say that the election of President Trump will not affect their marketing budgets.
- Five things for pharma marketers to know: Wednesday, March 22, 2017
- Five things for pharma marketers to know: Monday, March 20, 2017
- Novartis aims to bring first oral asthma drug to market in two decades
- Drugmakers target severe asthma patients with biologics, but payers raise pricing issue
- What five different pharma marketing careers look like
- 2017 Healthcare Marketers Trend Report: All the data in one place
- Infographic: What's next for the point of care market
- Drugmakers again boost DTC spending, to $5.6 billion in 2016
- Digital IDs become focus as drugmakers seek to track doctors' behavior online
- Some CME experts remain skeptical when it comes to social media